Scancell (LON:SCLP) Reaches New 12-Month Low – What’s Next?

Scancell Holdings plc (LON:SCLP) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as GBX 8.04 ($0.10) and last traded at GBX 8.19 ($0.10), with a volume of 987907 shares trading hands. The stock had previously closed at GBX 8.65 ($0.11).

Scancell Trading Down 5.3 %

The company has a market cap of £84.85 million, a price-to-earnings ratio of -12.56 and a beta of 0.35. The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The business’s fifty day simple moving average is GBX 9.75 and its two-hundred day simple moving average is GBX 12.98.

Scancell (LON:SCLP) last announced its quarterly earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. On average, equities analysts predict that Scancell Holdings plc will post -2.5361112 EPS for the current year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.